Pacira BioSciences, Inc. (NASDAQ:PCRX) Stock Has Average Price Target of $30.14 According to Brokerages

Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) have earned an average recommendation of “Hold” from the eleven analysts that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation and one has given a buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $33.33.

Several equities analysts have weighed in on the company. HC Wainwright downgraded Pacira BioSciences from a “buy” rating to a “hold” rating and dropped their price target for the stock from $38.00 to $36.50 in a research report on Friday. Zacks Research cut Pacira BioSciences from a “hold” rating to a “strong sell” rating in a report on Monday, October 5th. Needham & Company LLC downgraded Pacira BioSciences from a “buy” rating to a “hold” rating in a research report on Thursday. Oppenheimer began coverage on Pacira BioSciences in a research report on Wednesday, September 23rd. They issued an “outperform” rating and a $32.00 price objective on the stock. Finally, Jefferies Financial Group lowered Pacira BioSciences from a “buy” rating to a “hold” rating and set a $36.00 price objective on the stock. in a research note on Thursday.

Trending Headlines about Pacira BioSciences

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: Viatris agreed to buy Pacira for $36.50 per share in cash, valuing the equity at approximately $1.65 billion. The transaction gives shareholders a defined exit price and is expected to close by the end of 2026, subject to customary conditions. Viatris acquisition announcement
• Positive Sentiment: Viatris will add Pacira’s marketed non-opioid pain therapies, EXPAREL and ZILRETTA, along with a clinical-stage gene therapy candidate. Viatris expects the deal to expand its pain portfolio and be immediately accretive to its financial guidance metrics.
• Neutral Sentiment: RBC said a superior competing bid is unlikely, reducing the prospect of a higher offer but also lowering takeover uncertainty. The stock’s upside is therefore largely capped near the $36.50 consideration unless another bidder emerges. RBC superior bid analysis
• Neutral Sentiment: Analyst actions largely reflect the announced deal: JPMorgan upgraded PCRX to neutral, while RBC and Truist raised targets to $36.50 and maintained sector perform or hold ratings. HC Wainwright maintained neutral with a $36.50 target, and Jefferies kept hold with a $36.00 target.
• Negative Sentiment: Several shareholder-rights law firms are investigating whether Pacira’s board obtained fair value and conducted an adequate sale process. These investigations could create legal or procedural distractions, although no wrongdoing has been established. Shareholder investigation

Pacira BioSciences Trading Down 0.2%

Shares of PCRX opened at $36.31 on Tuesday. The company has a debt-to-equity ratio of 0.54, a current ratio of 5.04 and a quick ratio of 3.94. The firm has a 50 day simple moving average of $25.56 and a 200-day simple moving average of $24.59. Pacira BioSciences has a 1-year low of $18.80 and a 1-year high of $36.46. The stock has a market cap of $1.45 billion, a price-to-earnings ratio of 103.75 and a beta of 0.25.

Pacira BioSciences (NASDAQ:PCRX) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.08. Pacira BioSciences had a return on equity of 9.68% and a net margin of 1.96%. The firm had revenue of $192.40 million during the quarter, compared to the consensus estimate of $191.06 million. During the same period in the previous year, the firm posted $0.74 EPS. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. Equities analysts forecast that Pacira BioSciences will post 1.86 EPS for the current fiscal year.

Insider Activity

In other Pacira BioSciences news, insider Jonathan Slonin sold 3,040 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $23.23, for a total transaction of $70,619.20. Following the sale, the insider directly owned 216,384 shares of the company’s stock, valued at $5,026,600.32. This trade represents a 1.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Lauren Riker sold 6,000 shares of Pacira BioSciences stock in a transaction dated Thursday, October 8th. The stock was sold at an average price of $36.32, for a total transaction of $217,920.00. Following the sale, the senior vice president owned 62,284 shares of the company’s stock, valued at approximately $2,262,154.88. This trade represents a 8.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Pacira BioSciences

A number of institutional investors have recently modified their holdings of PCRX. Dimensional Fund Advisors LP lifted its stake in shares of Pacira BioSciences by 5.7% during the first quarter. Dimensional Fund Advisors LP now owns 2,060,597 shares of the company’s stock valued at $46,572,000 after buying an additional 110,584 shares during the period. Wellington Management Group LLP boosted its position in Pacira BioSciences by 17.8% during the second quarter. Wellington Management Group LLP now owns 563,458 shares of the company’s stock worth $14,295,000 after acquiring an additional 85,075 shares during the last quarter. Gagnon Securities LLC grew its stake in Pacira BioSciences by 11.5% in the 4th quarter. Gagnon Securities LLC now owns 501,211 shares of the company’s stock worth $12,971,000 after acquiring an additional 51,494 shares during the period. Bank of New York Mellon Corp purchased a new stake in Pacira BioSciences in the 2nd quarter worth approximately $7,532,000. Finally, Hillsdale Investment Management Inc. grew its stake in Pacira BioSciences by 7.5% in the 1st quarter. Hillsdale Investment Management Inc. now owns 331,300 shares of the company’s stock worth $7,487,000 after acquiring an additional 23,100 shares during the period. Institutional investors and hedge funds own 99.73% of the company’s stock.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain-management products. The company’s portfolio is designed to help manage acute and chronic pain while reducing reliance on traditional opioid therapies.

Its principal product is EXPAREL, an extended-release formulation of bupivacaine used to provide postsurgical pain relief. Pacira also markets ZILRETTA, an extended-release corticosteroid injection for osteoarthritis-related knee pain, and the iovera° system, a handheld cryoanalgesia device intended to temporarily block peripheral nerves and provide targeted pain relief.

Originally known as Pacira Pharmaceuticals, the company adopted the name Pacira BioSciences in 2018 to reflect its broader focus on innovative therapies and technologies.